Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice
- 16 September 2005
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 13 (4) , 367-374
- https://doi.org/10.1038/sj.cgt.7700893
Abstract
Linear polyethylenimine (L-PEI) is an efficient transfection agent for ovarian carcinoma cells in vitro and ex vivo. In the present work, we go a step further and evaluate the efficacy of L-PEI in human ovarian tumor nodes developed in mice. PEI/DNA complexes were administered intraperitoneally instead of intravenously to avoid sequestering of complexes in the lung and liver and to allow transfection of nonvascularized tumor nodes. Plasmid biodistribution was studied by PCR and gene expression was characterized using complementary luciferase and β-galactosidase assays. Intraperitoneal (i.p.) injection of L-PEI/DNA complexes allowed the straightforward distribution of plasmid in the whole peritoneal cavity. Gene expression occurred in many organs, but tumor nodes appeared as preferential sites for transgene expression. The i.p. delivery route allowed repeated injections and administration of large amounts of DNA (up to 400 μg) without signs of toxicity, even for doses well beyond the intravenous lethal dose. Transgene expression was dose-dependent and transient. However, multiple injections allowed its persistence to increase. These results provide encouraging elements towards the development of PEI-based gene therapy protocols for the treatment of advanced stage ovarian carcinoma.Keywords
This publication has 27 references indexed in Scilit:
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Polyethylenimine-Mediated Suicide Gene Transfer Induces a Therapeutic Effect for Hepatocellular Carcinoma in Vivo by Using an Epstein–Barr Virus-Based Plasmid VectorBiochemical and Biophysical Research Communications, 2002
- Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-UpGynecologic Oncology, 2001
- Side‐effects of a systemic injection of linear polyethylenimine–DNA complexesThe Journal of Gene Medicine, 2001
- Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI– p53 complexesCancer Gene Therapy, 2001
- Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954Gene Therapy, 1998
- Gene-Directed Enzyme Prodrug TherapyBioconjugate Chemistry, 1998
- ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivoGene Therapy, 1997
- ?Obstetrics & Gynecology, 1997
- In VivoGene Therapy of Ovarian Cancer by Adenovirus-Mediated Thymidine Kinase Gene Transduction and Ganciclovir AdministrationGynecologic Oncology, 1996